NYSE$HAE
Haemonetics Corp. · Q1 2025 earnings
Q1 2025 earnings · · Investor relations
Briefing
Haemonetics' first quarter performance showcased the strength and breadth of its products, impacting attractive high-growth markets.
Haemonetics reported an 8% increase in revenue to $336 million for the first quarter of fiscal year 2025. The company reaffirmed its fiscal year 2025 guidance for revenue, adjusted operating margin, adjusted earnings per diluted share, and free cash flow.
- First quarter fiscal 2025 revenue increased by 8.0% to $336.2 million compared to the same period last year.
- Earnings per diluted share were reported at $0.74, while adjusted earnings per diluted share reached $1.02.
- The company experienced cash outflow from operating activities of $27.4 million and a free cash outflow of $16.9 million.
- Haemonetics reaffirmed its fiscal 2025 GAAP total revenue and organic revenue growth guidance.
Headline financials
Revenue & EPS history
Haemonetics · Revenue · Quarterly
$336M
Revenue by segment
Haemonetics · $313M total across 3 segments · Q2 2024
- Plasma$142M+11.0%45.3%
- Hospital$103M+13.5%32.9%
- Blood Center$68.1M-7.6%21.7%
Forward guidance
The Company reaffirmed its previous fiscal 2025 GAAP total revenue and organic revenue growth guidance.
Tailwinds
- Plasma revenue decline between 3-6%.
- Blood Center revenue decline between 5-8%.
- Hospital revenue growth between 27-32%.
- Total company revenue growth between 5-8%.
- Organic growth between 0-3%.
Headwinds
- Currency impact of 0% to -1%.
- Acquisitions to contribute 5-6%.
- Adjusted operating margin between 23-24%.
- Adjusted earnings per diluted share between $4.45 - $4.75.
- Free cash flow between $130M - $180M.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q1 2025
+1.4%
Avg return
Earnings day
+4.1%
Avg return
5 days after
+6.5%
Avg return
30 days after
56%
38 / 68 earnings
Positive
+31.8%
Q2 2026
Best reaction
-15.0%
Q4 2016
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2026 | +3.3% | +2.5% | +35.5% | |
| Q3 2026 | -1.4% | -9.8% | -2.8% | |
| Q2 2026 | +31.8% | +41.4% | +65.5% | |
| Q4 2025 | +5.9% | +7.6% | +9.7% | |
| Q3 2025 | -11.6% | -13.6% | -3.6% | |
| Q2 2025 | +11.8% | +19.5% | +3.9% | |
| Q1 2025 | -10.1% | -13.4% | -14.6% | |
| Q4 2024 | +2.8% | +4.4% | -8.2% | |
| Q3 2024 | -3.8% | -7.0% | +3.2% | |
| Q2 2024 | +2.4% | +2.5% | -2.5% | |
| Q1 2024 | +2.0% | +3.0% | -0.8% | |
| Q4 2023 | +7.6% | +7.4% | +6.1% | |
| Q3 2023 | -5.4% | -8.2% | -12.2% | |
| Q2 2023 | +4.1% | -1.7% | +3.5% | |
| Q1 2023 | +8.1% | +12.3% | +13.7% | |
| Q4 2022 | +3.9% | +14.1% | +31.5% | |
| Q3 2022 | +21.2% | +24.5% | +18.9% | |
| Q2 2022 | -13.5% | -15.7% | -24.8% | |
| Q1 2022 | +8.4% | +1.8% | +16.8% | |
| Q4 2021 | -6.4% | -5.4% | +0.4% | |
| Q3 2021 | +12.8% | +21.1% | +4.0% | |
| Q2 2021 | -3.7% | +5.6% | +13.2% | |
| Q1 2021 | -12.7% | -8.5% | +3.3% | |
| Q4 2020 | -8.8% | -3.4% | -11.1% | |
| Q3 2020 | +7.2% | +7.7% | -7.3% | |
| Q2 2020 | +0.3% | +0.5% | -0.1% | |
| Q1 2020 | +10.5% | +13.5% | +10.8% | |
| Q4 2019 | +2.8% | +3.4% | +10.0% | |
| Q3 2019 | -12.2% | -14.3% | -13.0% | |
| Q2 2019 | +9.1% | +5.8% | -0.2% | |
| Q1 2019 | +4.8% | +2.7% | +14.4% | |
| Q4 2018 | +5.8% | +11.2% | +18.9% | |
| Q3 2018 | +14.8% | +13.1% | +20.5% | |
| Q2 2018 | +15.8% | +16.4% | +20.8% | |
| Q1 2018 | +4.2% | +3.2% | +3.9% | |
| Q4 2017 | -1.9% | -4.4% | -4.0% | |
| Q3 2017 | -10.1% | -9.0% | -7.3% | |
| Q2 2017 | +10.5% | +13.8% | +16.5% | |
| Q1 2017 | +13.8% | +16.8% | +22.6% | |
| Q4 2016 | -15.0% | — | — | |
| Q3 2016 | +5.9% | — | — | |
| Q2 2016 | -3.9% | — | — | |
| Q1 2016 | +1.5% | — | — | |
| Q4 2015 | -3.9% | — | — | |
| Q3 2015 | +7.0% | — | — | |
| Q2 2015 | -5.9% | — | — | |
| Q1 2015 | -1.4% | — | — | |
| Q4 2014 | -8.0% | — | — | |
| Q3 2014 | -2.6% | — | — | |
| Q2 2014 | +1.5% | — | — | |
| Q1 2014 | +0.7% | — | — | |
| Q4 2013 | -1.4% | — | — | |
| Q3 2013 | -5.6% | — | — | |
| Q2 2013 | +4.3% | — | — | |
| Q1 2013 | -0.1% | — | — | |
| Q4 2012 | +4.2% | — | — | |
| Q3 2012 | -1.0% | — | — | |
| Q2 2012 | +0.4% | — | — | |
| Q1 2012 | +3.1% | — | — | |
| Q4 2011 | +1.3% | — | — | |
| Q4 2009 | +1.3% | — | — | |
| Q3 2010 | -1.3% | — | — | |
| Q3 2011 | -1.3% | — | — | |
| Q2 2011 | +1.7% | — | — | |
| Q1 2010 | -2.5% | — | — | |
| Q2 2010 | -2.5% | — | — | |
| Q1 2011 | -2.5% | — | — | |
| Q4 2010 | -2.5% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro